Skip to main content

GlycoMimetics, Inc. (GLYC)

NASDAQ: GLYC · IEX Real-Time Price · USD
1.66
0.11 (7.10%)
At close: Dec 7, 2021 4:00 PM
1.67
0.01 (0.60%)
After-hours:Dec 7, 2021 6:50 PM EST
Market Cap85.89M
Revenue (ttm)1.31M
Net Income (ttm)-61.57M
Shares Out51.74M
EPS (ttm)-1.22
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume296,794
Open1.59
Previous Close1.55
Day's Range1.59 - 1.69
52-Week Range1.45 - 4.40
Beta1.88
AnalystsBuy
Price Target11.00 (+562.7%)
Earnings DateNov 2, 2021

About GLYC

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase 3 trial to treat relapsed/refractory A...

IndustryBiotechnology
IPO DateJan 10, 2014
CEORachel King
Employees54
Stock ExchangeNASDAQ
Ticker SymbolGLYC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for GlycoMimetics stock is "Buy." The 12-month stock price forecast is 11.00, which is an increase of 562.65% from the latest price.

Price Target
$11.00
(562.65% upside)
Analyst Consensus: Buy

News

NCI-Sponsored Trial of Uproleselan in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Completes En...

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company, announced today that the National Cancer Institute (NCI), part of the National Institutes of ...

1 day ago - Business Wire

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the compensation committee of the Company's Board of Directors approved the grant on November 22, ...

1 week ago - Business Wire

Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial in China of GlycoMimetics' Uproleselan for the Treatmen...

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Apollomics has dosed the first patient in China in a Phase 3 clinical trial of APL-106 (uproleselan injection) fo...

2 weeks ago - Business Wire

GlycoMimetics Appoints Regulatory Veteran Lisa DeLuca as Vice President, Regulatory Affairs

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Lisa DeLuca, Ph.D., has joined its executive leadership team as Vice President, Regulatory Affairs. Dr. DeLuca is...

2 weeks ago - Business Wire

GlycoMimetics Completes Enrollment of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan in Patients wi...

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced completion of enrollment of its pivotal Phase 3 trial evaluating uproleselan in addition to a standard chemotherapy re...

3 weeks ago - Business Wire

Hot Penny Stocks To Buy Now? 4 To Add To Your List Today

Are these on your list of penny stocks to watch today? The post Hot Penny Stocks To Buy Now?

Other symbols:DXFFLDMGRNQ
3 weeks ago - PennyStocks

GlycoMimetics GMI-1359 Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting and...

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that two abstracts relating to GMI-1359, the Company's dual antagonist of CXCR4 and E-selectin, have been accepted for...

3 weeks ago - Business Wire

GlycoMimetics to Present at Two Upcoming Healthcare Investor Conferences

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that Chief Executive Officer Harout Semerjian will present an overview of the company at the upcoming Stifel 2021 Vir...

4 weeks ago - Business Wire

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2021

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended September 30, 2021 and highlighted recent events. Cash and cash equivalents...

1 month ago - Business Wire

GlycoMimetics to Report Third Quarter Financial Results on November 2, 2021

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its third quarter financial results on Tuesday, November 2, ...

1 month ago - Business Wire

GlycoMimetics' Lead Candidate Data Published In An Online Journal

GlycoMimetics Inc (NASDAQ: GLYC) has announced that efficacy and safety data from a Phase 1/2 study of uproleselan were published online in the journal BLOOD.  In the manuscript, scientists highlighted ...

2 months ago - Benzinga

Efficacy and Safety Data for GlycoMimetics' Lead Investigational Drug Uproleselan Published in BLOOD

ROCKVILLE, Md.--(BUSINESS WIRE)--Efficacy and safety data from a Phase 1/2 clinical study of uproleselan, GlycoMimetics' lead investigational drug, were published online September 16, 2021 in the journa...

2 months ago - Business Wire

GlycoMimetics to Present at Upcoming H.C. Wainwright & Co Annual Global Investment Virtual Conference

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Harout Semerjian will present at the upcoming H.C. Wainwright & Co 23rd Annual Global Inv...

2 months ago - Business Wire

Implied Volatility Surging for GlycoMimetics (GLYC) Stock Options

Investors need to pay close attention to GlycoMimetics (GLYC) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2021

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended June 30, 2021 and highlighted recent events. Cash and cash equivalents at J...

4 months ago - Business Wire

GlycoMimetics Names Harout Semerjian as New Chief Executive Officer to Succeed Retiring CEO Rachel King

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that its Board of Directors has appointed Harout Semerjian as chief executive officer (CEO), effective August 6, 2021,...

4 months ago - Business Wire

GlycoMimetics to Report Second Quarter Financial Results on August 5, 2021

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its second quarter financial results on Thursday, August 5, ...

4 months ago - Business Wire

Trial Launches to Evaluate GlycoMimetics' Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians have treated the first patient in a Phase 1b/2 study evaluating the company's lead drug candidate, upr...

4 months ago - Business Wire

GlycoMimetics Announces Initiation of Clinical Trial Evaluating Uproleselan in Combination With Venetoclax and Azacit...

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians at University of California (UC) Davis Comprehensive Cancer Center initiated dosing of the first patie...

4 months ago - Business Wire

GlycoMimetics to Present at Jefferies 2021 Virtual Healthcare Conference

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that Chief Executive Officer Rachel King will provide a company overview at the Jefferies 2021 Virtual Healthcare Con...

6 months ago - Business Wire

GlycoMimetics Announces Investigator-Sponsored Phase 2 Clinical Trial Evaluating Uproleselan for Prevention of Gastro...

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians at Washington University School of Medicine in St. Louis have dosed the first patient in an investigat...

6 months ago - Business Wire

GlycoMimetics Reports Highlights and Financial Results for First Quarter 2021

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended March 31, 2021 and highlighted recent company events. Cash and cash equival...

7 months ago - Business Wire

GlycoMimetics to Report First Quarter Financial Results on May 3, 2021

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report first quarter financial results on Monday, May 3, 2021, at ...

7 months ago - Business Wire

GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancreatic Adenocarcin...

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that an abstract presenting the results of a recent preclinical study on the therapeutic effects of GMI-1757, a new gl...

7 months ago - Business Wire

Positive Findings From Phase 1b Trial of GlycoMimetics' GMI-1359 To Be Presented at AACR 2021 Meeting

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that a Phase 1b trial of GMI-1359, being conducted at Duke University Cancer Center, showed evidence of on-target effe...

7 months ago - Business Wire